Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Agenus and Incyte amend their high-profile immuno-oncology development deal.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-29 00:25:35.255028.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
As of 10:30 a.m EST, shares of the clinical-stage biotech Agenus (AGEN 0.06%) were up by more than 15%. This double-digit move northward was triggered by the news that Incyte (INCY 0.01%) and Agenus have amended their immuno-oncology licensing deal from a co-funded development and profit-sharing arrangement to a royalty-bearing program.
Breaking this news down, Agenus' shares are really shooting higher for three main reasons:
Image source: Getty Images.
From an outsider's vantage point, this amended agreement seems to be a prelude to a full-on buyout later on down the line. After all, Incyte has now agreed to up in its stake in Agenus to roughly 20% based on the latest available share count.
So perhaps the key takeaway from today's news is that Incyte is now firmly in the catbird seat as a potential buyer of Agenus if the biotech's checkpoint antibody platform hits pay dirt in the clinic. That's a critical development because other potential suitors may soon come calling based on the strong and growing interest in checkpoint inhibitors within the industry.
Although a buyout scenario isn't necessarily a smart reason to buy any stock, Agenus appears to be deeply undervalued in light of the stellar clinical track record of checkpoint inhibitors in general, as well as their enormous commercial potential that flat out dwarfs the company's $400 million market cap. As such, this speculative biotech is certainly worth a deeper dive by any risk-tolerant investor on the hunt for unusual growth opportunities.